The approval was based on a phase I/II trial, in which enasidenib as a single agent (100 mg daily) achieved an ORR of 40.3% with a median duration of response of 5.8 months and a median OS of 9.3 months in R/R IDH2-mutated AML patients. The gene discussed is IDH2; the disease is acute myeloid leukemia.